Re: Anyone here have Carcinoid Cancer?
"Home | Search | Browse | Resources | Help | What's New | About
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
This study is currently recruiting patients.
Sponsored by
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Purpose
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.
Condition Treatment or Intervention Phase
recurrent non-small cell lung cancerRecurrent Small Cell Lung Cancerrecurrent malignant mesotheliomarecurrent malignant thymomastage IIIB non-small cell lung cancerstage IV non-small cell lung cancerpulmonary carcinoid tumorlung metastases Procedure: hyperthermia Procedure: radiofrequency ablation Phase II
MEDLINEplus related topics: Asbestos/Asbestosis; Cancer (General); Cancer Alternative Therapy; Cancer--Living with Cancer; Carcinoid Tumors; Endocrine Diseases (General); Lung Cancer; Respiratory Diseases (General); Thymus Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of Radiofrequency Ablation in Patients With Refractory or Advanced Pulmonary Malignancies
Further Study Details:
OBJECTIVES:
Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
Determine the efficacy of this treatment, in terms of local control, in these patients.
Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.
OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.
Patients are followed at 1, 3, 6, and 12 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Eligibility
Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
Diagnosis of a primary or secondary intrathoracic malignancy
Any cell type or origin
Involving the intrapulmonary, mediastinal, or pleural/chest wall
Inoperable primary or metastatic cancer to the lung
Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
Single or multiple lesions that are non-contiguous with vital structures or organs such as:
Trachea
Heart
Aorta
Great vessels
Esophagus
Less than 5
cm in largest dimension
Accessible via percutaneous transthoracic route
PATIENT CHARACTERISTICS: Age:
Not specified
Performance status:
Not specified
Life expectancy:
Not specified
Hematopoietic:
Not specified
Hepatic:
Coagulation profile normal
Renal:
Not specified
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
Location and Contact Information
California
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, 90095-1781, United States; Recruiting
Robert D. Suh, MD 310-794-2168
Study chairs or principal investigators
Robert D. Suh, MD, Study Chair, Jonsson Comprehensive Cancer Center
More Information
Study ID Numbers CDR0000068889; UCLA-9908024; NCI-G01-2011
Record last reviewed September 2001
NLM Identifier NCT00024076
ClinicalTrials.gov processed this record on 2003-06-24
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act"
Good Luck